Association of HLA-B*1502 and *1511 allele with antiepileptic drug-induced Stevens-Johnson syndrome in central China

Abstract

Previous studies have demonstrated a strong association between carbamazepine (CBZ)-induced Stevens-Johnson syndrome (SJS) and HLA-B*1502 in Han Chinese. Here, we extended the study of HLA-B*1502 susceptibility to two different antiepileptic drugs, oxcarbazepine (OXC) and phenobabital (PB). In addition, we genotyped HLA-B*1511 in a case of CBZ-induced SJS with genotype negative for HLA-B*1502. The presence of HLA-B*1502 was determined using polymerase chain reaction with sequence-specific primers (PCR-SSP). Moreover, we genotyped HLA-B*1502 in 17 cases of antiepileptic drugs (AEDs)-induced cutaneous adverse drug reactions (cADRs), in comparison with AEDs-tolerant (n=32) and normal controls (n=38) in the central region of China. The data showed that HLA-B*1502 was positive in 5 of 6 cases of AEDs-induced SJS (4 CBZ, 1 OXC and 1 PB), which was significantly more frequent than AEDs-tolerant (2/32, 18 CBZ, 6 PB and 8 OXC) and normal controls (3/38). Compared with AEDs-tolerant and normal controls, the OR for patients carrying the HLA-B*1502 with AEDs-induced SJS was 6.25 (95% CI: 1.06–36.74) and 4.86 (95% CI: 1.01–23.47). The sensitivity and specificity of HLA-B*1502 for prediction of AEDs-induced SJS were 71.4%. The sensitivity and specificity of HLA-B*1502 for prediction of CBZ-induced SJS were 60% and 94%. HLA-B*1502 was not found in 11 children with maculopapular exanthema (MPE) (n=9) and hypersensitivity syndrome (HSS) (n=2). However, we also found one case of CBZ-induced SJS who was negative for HLA-B*1502 but carried HLA-B*1511. It was suggested that the association between the CBZ-induced SJS and HLA-B*1502 allele in Han Chinese children can extend to other aromatic AEDs including OXC and PB related SJS. HLA-B*1511 may be a risk factor for some patients with CBZ-induced SJS negative for HLA-B*1502.

Keywords

Stevens-Johnson syndrome / antiepileptic drugs / children / HLA-B*1511 / HLA-B*1502

References

[1] RoujeauJC, SternRS. Severe adverse cutaneous reactions to drugs. New Engl J Med, 1994, 331(19): 1272-1285

[2] HungSI, ChungWH, JeeSH, et al.. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics, 2006, 16(4): 297-306

[3] LimKS, KwanP, TanCT. Association of HLA-B*1502 allele and carbamazepine-induced severe adverse cutaneous drug reaction among Asians, a review. Neurology Asia, 2008, 13(6): 15-21

[4] ChangCC, TooCL, MuradS, et al.. Association of HLAB*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population. Int J Dermatol, 2011, 50(2): 221-224

[5] OzekiT, MushirodaT, YowangA, et al.. Genome-wide association study identifies HLAA*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet, 2011, 20(5): 1034-1041

[6] ManCB, KwanP, BaumL, et al.. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia, 2007, 48(5): 1015-1018

[7] BunceM, O’NeillCM, BarnardoMC, et al.. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens, 1995, 46(5): 355-367

[8] LonjouC, ThomasL, BorotNRegiSCAR Group, et al.. A marker for Stevens-Johnson syndrome ethnicity matters. Pharmacogenomics J, 2006, 6(4): 265-268

[9] ChungWH, HungSI, HongHS, et al.. Medical genetics: a marker for Stevens-Johnson syndrome. Nature, 2004, 428(6982): 486

[10] LocharernkulC, LoplumlertJ, LimotaiC, et al.. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia, 2008, 49(12): 2087-2091

[11] IkedaH, TakahashiY, YamazakiE, et al.. HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions. Epilepsia, 2010, 51(2): 297-300

[12] AlfirevicA, JorgensenAL, WilliamsonPR, et al.. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics, 2006, 7(6): 813-818

[13] MehtaTY, PrajapatiLM, MittalB, et al.. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol, 2009, 75(6): 579-582

[14] WuXT, HuFY, AnDM, et al.. Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients. Epilepsy Behav, 2010, 19(3): 405-408

[15] TassaneeyakulW, TiamkaoS, JantararoungtongT, et al.. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia, 2010, 51(5): 926-930

[16] ZhangY, WangJ, ZhaoLM, et al.. Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients. Eur J Clin Pharmacol, 2011, 67(9): 885-887

[17] WangQ, ZhouJQ, ZhouLM, et al.. Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland. Seizure, 2011, 20(6): 446-448

[18] ShiYW, MinFL, QinB, et al.. Association between HLA and Stevens-Johnson syndrome induced by carbamazepine in Southern Han Chinese: genetic markers besides B*1502?. Basic Clin Pharmacol Toxicol, 2012, 111(1): 58-64

[19] KulkantrakornK, TassaneeyakulW, TiamkaoS, et al.. HLA-B*1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain. Pain Pract, 2012, 12(3): 202-208

[20] KaniwaN, SaitoY, AiharaM, et al.. HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia, 2010, 51(12): 2461-2465

[21] KnowlesSR, ShapiroLE, ShearNH. Anticonvulsion hypersensitivity syndrome: incidence, prevention and management. Drug Saf, 1999, 21(6): 489-501

[22] HirschLJ, ArifH, NahmEA, et al.. Cross-sensitivity of skin rashes with antiepileptic drug use. Neurology, 2008, 71(19): 1527-1534

[23] AlvestadS, LydersenS, BrodtkorbE. Cross-reactivity pattern of rash from current aromatic antiepileptic drugs. Epilepsy Res, 2008, 80(23): 194-200